Search Prime Grants

UG1EY028091

Cooperative Agreement

Overview

Grant Description
Adalimumab vs. conventional immunosuppression for uveitis (ADVISE) trial.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Maryland United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 08/31/25 and the total obligations have increased 1087% from $758,746 to $9,004,458.
The Johns Hopkins University was awarded ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial Cooperative Agreement UG1EY028091 worth $9,004,458 from National Eye Institute in September 2018 with work to be completed primarily in Maryland United States. The grant has a duration of 7 years and was awarded through assistance program 93.867 Vision Research. The Cooperative Agreement was awarded through grant opportunity NEI Clinical Vision Research: Coordinating Center Grant (UG1).

Status
(Complete)

Last Modified 8/5/24

Period of Performance
9/30/18
Start Date
8/31/25
End Date
100% Complete

Funding Split
$9.0M
Federal Obligation
$0.0
Non-Federal Obligation
$9.0M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UG1EY028091

Subgrant Awards

Disclosed subgrants for UG1EY028091

Transaction History

Modifications to UG1EY028091

Additional Detail

Award ID FAIN
UG1EY028091
SAI Number
UG1EY028091-2100433252
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Funding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Awardee UEI
FTMTDMBR29C7
Awardee CAGE
5L406
Performance District
MD-90
Senators
Benjamin Cardin
Chris Van Hollen

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) Health research and training Grants, subsidies, and contributions (41.0) $9,037,917 100%
Modified: 8/5/24